Like Bio-Hermes-001, the Bio-Hermes-002 study is paving the way for improving participation by trial participants who are traditionally underrepresented in Alzheimer’s clinical research, with an ...

About the Cystic Fibrosis Trust Cystic Fibrosis Trust is the only UK-wide charity dedicated to uniting for a life unlimited for everyone affected by cystic fibrosis. The Trust funds cutting edge ...

An exciting opportunity has arisen to join a national research programme with the aim of speeding up the diagnosis and treatment of rare respiratory diseases. The LifeArc Centre for Rare Respiratory ...

This transgenic model of tauopathy expresses MAPT with the P301S mutation, which is associated with autosomal-dominant disease in humans. The hTau.P301S model recapitulates several molecular, cellular ...

LONDON, Jan. 30, 2025 /PRNewswire/ -- LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced substantial progress in 2024, with three ...

Lifearc has announced a collaboration with Neuropeutics Inc. to develop a new small molecule for the treatment of motor neuron disease (MND), or amyotrophic lateral sclerosis (ALS). Neuropeutics and ...

TORONTO, Jan. 27, 2025 /CNW/ - Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic ...

TORONTO, Jan. 27, 2025 /CNW/ - Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic ...

Leveraging the unique capabilities and respective strengths of both organisations, Neuropeutics Inc and LifeArc aim to develop a lead candidate therapeutic to prevent and reverse TDP-43 protein ...